TP53 and neoplasm: Further studies focused on the evaluation of the effect of C‐1305 on the topoisomerase II activity showed that treatment with C‐1305 led to the formation of low levels of potent cleavable complexes that are selectively toxic toward tumour cells with impaired p53 function.9